Emergent BioSolutions (EBS) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Emergent BioSolutions (EBS) over the past year, losing 38.6% versus a loss of 49.7%. Over five years, RLMD leads with a -86.1% price change compared with -88.6% for EBS. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $259.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | RLMD |
|---|---|---|
| Share price | $5.05 | $2.62 |
| Market cap | $259.65M | $279.54M |
| 1-day change | -1.94% | -15.76% |
| YTD return | -59.14% | -45.76% |
| 1-year return | -49.70% | -38.64% |
| 5-year return | -88.58% | -86.09% |
| Forward P/E | 4.83 | — |
| EPS (TTM) | $-5.00 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $742.90M | — |
| Revenue growth (YoY) | -28.81% | — |
| Net income (latest FY) | $52.60M | $-57.39M |
| Gross margin | 56.09% | — |
| Operating margin | 13.47% | — |
| Net margin | 7.08% | — |
| 52-week high | $14.06 | $8.00 |
| 52-week low | $4.36 | $2.60 |
| Distance from 52-week high | -64.08% | -67.25% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.02% | +310.31% |
| Average volume | 1.11M | 1.45M |
| Shares outstanding | 51.42M | 106.69M |
| Employees | 900 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed EBS by 11.1 percentage points over the past year.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
EBS vs RLMD FAQ
Which is bigger, Emergent BioSolutions or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $259.65M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.